Emmanuelle Soleilhac

Title: Emmanuelle Soleilhac: Innovator in Cancer Treatment

Introduction

Emmanuelle Soleilhac is a prominent inventor based in St Etienne de Crossey, France. She has made significant contributions to the field of cancer treatment through her innovative research and patented inventions. With a total of 2 patents, her work focuses on developing novel therapeutic approaches for various cancers.

Latest Patents

One of her latest patents is titled "Heterocyclic naphthoquinones derivatives for use in the treatment of cancers including Cushing disease." This invention concerns the use of heterocyclic naphthoquinones derivatives to treat Cushing disease and other cancers, particularly through the inhibition of Ubiquitin Specific Proteases (USP) 8 and/or 2. Another significant patent is "Synthetic lethal drug combination for treating renal cell carcinoma." This invention presents a novel treatment for renal cell carcinoma and other solid tumors that harbor VHL inactivation, based on a combination of a first agent inhibiting protein kinase CK2 and a second agent inhibiting Ataxia Telangiectasia Mutated (ATM) kinase.

Career Highlights

Emmanuelle has worked with esteemed organizations such as the Commissariat à l'Énergie Atomique et aux Énergies Alternatives and the Université d'Aix-Marseille. Her work in these institutions has allowed her to advance her research and contribute to the scientific community.

Collaborations

Throughout her career, Emmanuelle has collaborated with notable colleagues, including Catherine Pillet and Caroline Barette. These partnerships have enriched her research and fostered innovation in her field.

Conclusion

Emmanuelle Soleilhac is a dedicated inventor whose work in cancer treatment showcases her commitment to advancing medical science. Her innovative patents and collaborations highlight her significant contributions to the field.